Drugs / ECI830
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06726148 | Apr 2025 → Sep 2028 expected | hormone receptor-positive breast cancer, small cell lung carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ECI830 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06726148 ↗ |